59.94
price down icon0.61%   -0.37
after-market アフターアワーズ: 59.01 -0.93 -1.55%
loading
前日終値:
$60.31
開ける:
$58.39
24時間の取引高:
4.42M
Relative Volume:
1.68
時価総額:
$11.52B
収益:
$2.95B
当期純損益:
$523.88M
株価収益率:
22.28
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
+4.88%
1か月 パフォーマンス:
+3.86%
6か月 パフォーマンス:
+5.42%
1年 パフォーマンス:
-8.99%
1日の値動き範囲:
Value
$57.84
$61.48
1週間の範囲:
Value
$57.26
$61.48
52週間の値動き範囲:
Value
$50.76
$73.51

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1112)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,040
Name
Twitter
Name
次回の収益日
2025-10-27
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
59.94 11.59B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2026-01-20 アップグレード Canaccord Genuity Hold → Buy
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
05:53 AM

Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights

05:53 AM
pulisher
04:33 AM

BioMarin Raises $850 Million Notes for Amicus Acquisition - TipRanks

04:33 AM
pulisher
04:13 AM

BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView

04:13 AM
pulisher
04:05 AM

BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan

04:05 AM
pulisher
12:44 PM

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga

12:44 PM
pulisher
12:17 PM

BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex

12:17 PM
pulisher
11:33 AM

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive

11:33 AM
pulisher
11:22 AM

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz

11:22 AM
pulisher
10:56 AM

Baird maintains BioMarin stock rating amid competitor’s positive trial data By Investing.com - Investing.com India

10:56 AM
pulisher
10:47 AM

Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com

10:47 AM
pulisher
07:31 AM

BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters

07:31 AM
pulisher
01:03 AM

BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace

01:03 AM
pulisher
Feb 11, 2026

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - bitget.com

Feb 11, 2026
pulisher
Feb 11, 2026

Pharma companies left out of Trump's drug-pricing deals look for way in - marketscreener.com

Feb 11, 2026
pulisher
Feb 11, 2026

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz

Feb 11, 2026
pulisher
Feb 11, 2026

Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz

Feb 11, 2026
pulisher
Feb 11, 2026

Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia - marketscreener.com

Feb 11, 2026
pulisher
Feb 11, 2026

BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Feb 11, 2026
pulisher
Feb 08, 2026

Acquisition plans to fuel BioMarin Pharmaceutical (BMRN), according to Barclays - MSN

Feb 08, 2026
pulisher
Feb 08, 2026

What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? - Finviz

Feb 08, 2026
pulisher
Feb 08, 2026

BioMarin Pharmaceutical Stock Outlook Looks Promising - Intellectia AI

Feb 08, 2026
pulisher
Feb 08, 2026

BioMarin’s Strategic Acquisition Nears Critical Data Readout - AD HOC NEWS

Feb 08, 2026
pulisher
Feb 07, 2026

Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays - Finviz

Feb 07, 2026
pulisher
Feb 07, 2026

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum - Sahm

Feb 07, 2026
pulisher
Feb 06, 2026

Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Benzinga

Feb 06, 2026
pulisher
Feb 06, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $84.00 at Piper Sandler - MarketBeat

Feb 06, 2026
pulisher
Feb 05, 2026

The Best Biotech Stocks to Buy - Morningstar

Feb 05, 2026
pulisher
Feb 05, 2026

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Feb 05, 2026
pulisher
Feb 05, 2026

Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Feb 05, 2026
pulisher
Feb 04, 2026

Achondroplasia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - Barchart.com

Feb 04, 2026
pulisher
Feb 04, 2026

AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Feb 04, 2026
pulisher
Feb 03, 2026

BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo - Bloomberg Law News

Feb 03, 2026
pulisher
Feb 02, 2026

BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook on a Biotech Leader with 60% Upside Potential - DirectorsTalk Interviews

Feb 02, 2026
pulisher
Feb 02, 2026

BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter

Feb 02, 2026
pulisher
Feb 01, 2026

California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN

Feb 01, 2026
pulisher
Feb 01, 2026

(BMRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Feb 01, 2026
pulisher
Feb 01, 2026

The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha

Feb 01, 2026
pulisher
Feb 01, 2026

BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc. - MarketBeat

Feb 01, 2026
pulisher
Jan 31, 2026

Investors Holding Back On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛

Jan 31, 2026
pulisher
Jan 31, 2026

Should You Buy BioMarin Pharmaceutical Before Feb. 18? - Finviz

Jan 31, 2026
pulisher
Jan 30, 2026

BioMarin prices $850 million in senior notes to fund Amicus acquisition - Investing.com India

Jan 30, 2026
pulisher
Jan 29, 2026

BioMarin Secures Major Debt Financing for Amicus Acquisition - TipRanks

Jan 29, 2026
pulisher
Jan 29, 2026

BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication - TradingView

Jan 29, 2026
pulisher
Jan 29, 2026

BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility - Chartmill

Jan 29, 2026
pulisher
Jan 29, 2026

Hussman Strategic Advisors Inc. Takes $1.14 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Jan 29, 2026
pulisher
Jan 29, 2026

BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Jan 29, 2026
pulisher
Jan 29, 2026

BioMarin Weighs Amicus Deal And Billions In New Debt Financing - simplywall.st

Jan 29, 2026
pulisher
Jan 28, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Barclays - MarketBeat

Jan 28, 2026
pulisher
Jan 28, 2026

Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) - Finviz

Jan 28, 2026
pulisher
Jan 27, 2026

Assessing BioMarin Pharmaceutical (BMRN) Valuation As Investors Revisit The Rare Disease Specialist - Sahm

Jan 27, 2026
pulisher
Jan 27, 2026

Double-digit Revenue Growth Till 2030 Drives BioMarin’s (BMRN) Bullish Thesis - Insider Monkey

Jan 27, 2026

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):